This Healthcare Fund Thinks Large-Caps Are The Best Way To Go

The next large-cap up for review is Gilead Sciences Inc (NASDAQ:GILD), in which HealthInvest reported having some 240,300 shares with a market value of $27.11 million at the halfway point of the year. Gilead Sciences Inc (NASDAQ:GILD) is another biopharmaceutical monster, with a $165.82 billion market cap. During this year alone the stock of the company has returned some 19.7% and the mean analysts’ estimates still imply a 10.36% upside from the $112.83 at which the equity is currently changing hands. Donald Chiboucis’ Columbus Circle Investors held 4.17 million shares of Gilead Sciences Inc (NASDAQ:GILD) worth $409.03 million as of March 31.

Finally, HealthInvest finished the latest 13F reporting period with 170,700 shares of Anthem Inc (NYSE:ANTM), worth $25.75 million. Over the second quarter of the year, the fund added around 55.61% to its position in the respected stock. Anthem Inc (NYSE:ANTM) traded sideways during much of the April-June period, yet managed to close in the green by 6.28%. Since then, the price has declined by some 8.2% however, following the news that it would buy CIGNA Corporation (NYSE:CI) for about $54.2 billion, leading to large net money outflows from the stock. Larry Robbins’s Glenview Capital led the list of the largest equity holders of Anthem Inc (NYSE:ANTM) as of March 31, holding 4.89 million shares worth $755.62 million.

Disclosure: None